GSK's agreement to pay up to $2.2bn settles 93% of US lawsuits over Zantac, while also addressing a whistleblower claim without admitting wrongdoing.
The settlements reduce GSK's financial uncertainties tied to protracted litigation stemming from concerns that Zantac's key ingredient could increase cancer risk.
Zantac, once the world’s best-selling drug, was pulled from the US market in 2020 due to potential cancer-causing properties of its component, ranitidine.
Despite GSK's settlements and past issues, Zantac 360, which does not contain ranitidine, continues to be sold.
Collection
[
|
...
]